hims - Search News

Hims, Hers

Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor

With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears "aspirational."

Modern Healthcare · 3d

Hims & Hers' stock plunges as semaglutide shortage ends

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a growing group of telehealth companies such as Hims & Hers that have built businesses around offering cheaper copies of the branded medications.

Money Morning · 4d

Why Is HIMS Stock Down So Much? Should You Buy?

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which previously allowed Hims & Hers to sell compounded alternatives. Compounded versions were permitted during the shortage but are now restricted unless they meet specific exceptions.

Hims & hers health, co

CNBC on MSN · 1h

Hims & Hers shares plunge 28% on concerns over weight loss business, margins

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future of its weight loss business.

Reuters · 18h

Hims & Hers warns it may stop selling compounded weight-loss drugs

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.

Wall Street Journal · 3h

Novo Nordisk Stock Rises on Weight-Loss Retreat by Hims & Hers

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood about 17% lower at under $42.

21m

Hims & Hers Stock Crashed 26% Today. Here's What You Need to Know

Hims & Hers ( HIMS -28.24%) continues to grow at an astounding rate as the company grows subscribers and revenue per subscriber. But Hims & Hers stock is falling after earnings because investors are ...

4hon MSN

Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

ktvq26m

Hims and Hers likely to stop selling cheaper versions of GLP-1 medications

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

4hon MSN

Why Hims & Hers Health Inc. (HIMS) Went Up On Monday?

We recently published a list of 10 Stocks Grow Firmer Despite Mixed Market Sentiment. In this article, we are going to take a ...

19h

HIMS Earnings: Shares Sink despite Smashing Guidance Estimates

Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth ...

15h

Hims & Hers offers upbeat forecast, but stock slides after hours

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

HIMS Earnings Preview: Will The Stock Rebound After 25% Drop?

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity

Hims & Hers dipped 19% post-Q4 earnings. Read here for HIMS stock's growth trends, margin concerns, and why this could be a ...

1hon MSN

Hims & Hers shares plunge as looming curbs on drug compounding cloud forecast

Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Hims, Hers

Hims & hers health, co

Related topics